# Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

> **NCT00859001** · PHASE2 · COMPLETED · sponsor: **University of Bologna** · enrollment: 55 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** FM+R
- **DRUG:** Zevalin (Ibritumomab Tiuxetan)

## Key facts

- **NCT ID:** NCT00859001
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2009-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859001, "Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00859001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*